David Dubinsky

David Dubinsky is the Chief Financial Officer of Oberland Capital, a New York–based investment firm specializing in flexible, non-dilutive structured financing for the global healthcare industry. In this role he oversees the firm's financial operations, accounting, fund administration, and reporting functions for a manager with approximately $3.2 billion in assets under management across multiple Healthcare Royalty and Credit Opportunities funds.

Before joining Oberland Capital, Dubinsky was a Managing Director and CFO at Siguler Guff & Company, a diversified private equity firm with more than $10 billion in assets under management, where he oversaw the firm's accounting and client reporting functions. Earlier in his career, he was a Manager within the Assurance & Advisory Business Services department at Ernst & Young, gaining a foundation in audit and financial advisory for institutional clients.

Dubinsky holds a B.S. in Accounting from Binghamton University (State University of New York) and is a Certified Public Accountant (CPA) in the State of New York. His profile is that of a finance and operations executive — a CFO with deep private-equity and fund-accounting experience — rather than a deal-sourcing investment partner.

As CFO, Dubinsky is not the firm's deal originator; the points below describe the strategy of Oberland Capital, the platform he helps run financially:

• Non-dilutive, structured capital: Oberland provides financing that lets healthcare companies raise capital without issuing new equity — typically in exchange for rights to future product royalties or revenue streams.
• Flexible structures: A broad suite of solutions including monetization of royalty streams, acquisition of future product revenues, project-based (synthetic) financing, and investments in debt and equity securities.
• Deal size: Target transactions of roughly $50M–$300M, with the ability to underwrite significantly larger deals.
• Stage: Focus on commercial-stage and near-commercial-stage products and late-stage clinical assets, financing late-stage trials and commercial build-outs; will consider select earlier-stage opportunities.
• Firm positioning (own words): "Healthcare Specialists Passionate About Innovation" — the team emphasizes combined scientific, operational, and financial expertise and customizes structures "to meet the specific capital requirements and strategic objectives of transaction partners globally."